Bayer sells testosterone drug rights to Grünenthal for €500m
pharmaphorum
JULY 14, 2022
The legacy product now lies outside Bayer’s core areas of cardiology, oncology, haematology, ophthalmology, women’s health and radiopharmaceuticals, and the funds raised from the sale will support the “ongoing transformation of Bayer’s pharma business to focus on key areas of future medical innovation”, said the company.
97 
Let's personalize your content